Nuvation Bio to Raise $200M via Convertible Notes, Repay Senior Loan
NUVB has more than doubled off its 52-week low of $1.81 on elevated volume (2.2× avg).
Summary
Nuvation Bio announced a proposed $200 million offering of convertible senior notes due 2032, with an option for an additional $30 million. The proceeds are intended to repay a senior secured loan and fund general corporate purposes, which should strengthen the company's balance sheet and provide operational flexibility. This follows the company's positive Q1 2026 financial results, which included positive operating cash flow. Capped call transactions are expected to reduce potential dilution from the notes. The final terms, including interest and conversion rates, will be set at pricing.
At the time of this announcement, NUVB was trading at $6.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $1.81 to $9.75. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: PR Newswire.